Henry Schein, Inc. HSIC recently added a new feather to its cap by acquiring the orthopedic specialist, TriMed. The addition of TriMed’s expertise in lower extremity (foot and ankle) and upper extremity (hand and wrist) treatments is poised to give HSIC a broader arsenal to cater to Integrated Delivery Networks and Ambulatory Surgery Center patrons. This strategic move not only expands the company’s foothold in the orthopedic niche but also solidifies its rapport with existing clientele.
TriMed, headquartered in Santa Clarita, CA, brings a wealth of knowledge and innovation to the orthopedic space, aligning perfectly with Henry Schein’s vision of capitalizing on burgeoning markets.
The deal, which kicked off in December 2023, is forecasted to have a neutral to non-GAAP earnings per share impact in 2024, turning accretive thereafter.
Reinforcing Strategic Positioning
The collaboration with TriMed is set to catapult Henry Schein into a leading role in the orthopedic domain, specifically in the Foot and Ankle as well as Hand and Wrist sectors. By leveraging TriMed’s skilled leadership and comprehensive product portfolio, HSIC aims to maximize its influence among Integrated Delivery Networks and Ambulatory Surgery Centers.
According to company executives, the foray into extremity treatments complements Henry Schein’s existing line of Brasseler Medical orthopedic cutting accessories and revision instrument solutions.
The upper and lower extremity segments are burgeoning realms within orthopedics, collectively representing a market potential exceeding $5.5 billion. With the integration of TriMed’s offerings, Henry Schein is primed to catapult its global outreach, tapping into the rapidly expanding extremity market.
Image Source: Zacks Investment Research
Market Outlook
A recent report by Grand View Research estimated the global orthopedic devices market at $72.9 billion in 2023, with projections indicating a compound annual growth rate of 5.3% from 2024 to 2030. This bullish market trajectory is propelled by factors such as a surge in orthopedic disorders, a rapidly aging population, degenerative bone conditions, and a rise in road accidents. Additionally, the escalating incidence of musculoskeletal issues triggered by sedentary lifestyles and obesity is expected to fuel further market expansion.
Stock Performance Overview
Over the past year, HSIC’s stock has experienced a 13.2% decline, juxtaposed against the broader medical dental supplies industry which has seen a growth of 9.5%.
Market Analysis and Recommendations
Currently, Henry Schein holds a Zacks Rank #3 (Hold). For investors seeking potential alternatives in the medical sector, stocks like DaVita DVA, Stryker SYK, and Cardinal Health CAH come recommended. DaVita has a Zacks Rank #1 (Strong Buy), while Stryker and Cardinal Health sport a Zacks Rank #2 (Buy). A catalyst for these choices stems from DaVita’s remarkable 65.3% surge in the past year and consistent earnings projections. Similarly, Stryker and Cardinal Health offer stable growth prospects, with healthy stock performances to date.
DaVita’s ascension in earnings estimates, along with its impressive track record of beating projections, showcases strong potential for investors. On the other hand, Stryker’s stock growth of 21.5% over the last year and consistent earnings outperformance underscore its resilience. Cardinal Health, boasting a significant 45% surge in stock price, has consistently surpassed earnings estimates, painting a positive outlook for investors.
The broader financial landscape and strategic acquisitions propelled by Henry Schein reflect a promising trajectory for TriMed and Extremity, underpinning the company’s commitment to sustainable growth and market leadership.
Delve into the Stock Market ChatGPT Wisdom
Zacks Senior Stock Strategist, Kevin Cook, unveils 5 hand-chosen stocks in the dynamic Artificial Intelligence sector with massive growth potential. By 2030, the AI industry is set to revolutionize global economics, akin to the impact of the internet and the iPhone.
Embark on this investment journey today, as automation takes the reins in answering inquiries, addressing missteps, challenging narratives, and vetoing irrelevant requests. As one industry frontrunner put it, “Automation liberates individuals from mundane tasks, empowering them to achieve the extraordinary.”
Claim Your Complimentary ChatGPT Stock Report Now >>
Explore the Free Stock Analysis Report for Stryker Corporation (SYK)
Discover the Free Stock Analysis Report for DaVita Inc. (DVA)
Uncover the Free Stock Analysis Report for Cardinal Health, Inc. (CAH)
Check out the Free Stock Analysis Report for Henry Schein, Inc. (HSIC)
For further details, read the full article on Zacks.com.
Explore Zacks Investment Research for more insights.
Please note that the opinions voiced herein are purely those of the author and not necessarily reflective of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
